YAVNE, Israel — August 14, 2025 — Leads & Copy — MediWound Ltd. (Nasdaq: MDWD) reported its Q2 2025 financial results, highlighting a 43% revenue increase to $5.7 million compared to the previous quarter. The company’s VALUE Phase III trial for EscharEx® continues to enroll patients, with strategic research collaborations established with Essity and Convatec.
CEO Ofer Gonen noted progress across clinical, commercial, and operational objectives. The NexoBrid® manufacturing expansion is on track for full operational capacity by year-end 2025.
Key developments include ongoing enrollment in the EscharEx® VALUE Phase III study, new collaborations with Essity and Convatec, and continued U.S. adoption of NexoBrid®, with Vericel reporting 52% year-over-year revenue growth.
MediWound’s expanded manufacturing facility is on schedule, and the company received an additional $3.6 million from the U.S. Department of Defense to advance a room temperature-stable formulation of NexoBrid®.
Hani Luxenburg, Chief Financial Officer
Daniel Ferry, Managing Director, LifeSci Advisors, LLC, daniel@lifesciadvisors.com
Ellie Hanson, FINN Partners for MediWound, ellie.hanson@finnpartners.com, +1-929-588-2008
Source: MediWound Ltd.
